TrialNature medicine2019

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Timothy F Cloughesy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.